Non-Hodgkin Lymphoma (NHL) Treatment Regimens: AIDS-Related B-Cell Lymphoma
View a treatment regimen chart for AIDS-related B-cell lymphoma, with detailed information based on condition (ie, Burkitt lyphoma, Castleman’s Disease).
Lymphoma
Hodgkin Lymphoma Treatment Regimens
Find comprehensive treatment regimens for Hodgkin lymphoma, including therapies such as ABVD + involved-field radiotherapy and more.
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Survival Worse for Nonwhite Children With Hodgkin Lymphoma
Risk for postrelapse mortality 2.7-, 3.5-fold higher for Hispanics, non-Hispanic blacks versus whites.
Older Patients With Follicular Lymphoma Benefit From Appropriate Therapy
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
Allo-HSCT in DLBCL: Cord Blood May Be a Suitable Source of Stem Cells
Results of a retrospective study showed allogeneic hematopoietic stem cell transplantation (allo-HSCT) using cord blood-derived stem cells was an effective approach to the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients With DLBCL
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Next post in ASH 2019
